Design: Cross-sectional analysis of trial screening data
Population: 15,612 cognitively unimpaired adults aged 55–80 across 4 world regions
Primary outcome: Plasma %p-tau217 and its association with amyloid PET and cognition
Effect: Lower %p-tau217 in Asian, Black and Hispanic groups; PET association consistent across races

Screening data from the AHEAD 3-45 preclinical Alzheimer trial, in JAMA Neurology (12 October), covered 15,612 adults aged 55 to 80 at 106 sites in four world regions.

Plasma p-tau217 percentage was lower in Asian, Black and Hispanic participants than in White and non-Hispanic participants. APOE ε4 raised levels in every group, but by different amounts. Importantly, the relation between p-tau217 and amyloid PET, and between p-tau217 and cognition, did not differ between racial groups, though it did differ by Hispanic ethnicity.

As blood tests for Alzheimer pathology move into clinics, a single cut-off derived mostly from White populations may misclassify others. For now the finding supports using p-tau217 to select who goes on to PET, not as a stand-alone diagnosis.

Plasma p-tau217 levels differed by race and ethnicity at the population level
Its relation to amyloid PET was consistent across racial groups
Use blood biomarkers to triage for confirmatory testing, not to diagnose alone
Indian-specific reference data are lacking; interpret cut-offs cautiously

Why it matters

Blood-based Alzheimer tests are spreading faster than the reference data for non-White populations.

The statistics, in plain English

The race-by-APOE interaction (P <0.001) means the size of the APOE effect varied by group, not that the test works differently. Differences in average level matter most near a decision threshold.